News

Ceres Nanosciences receives $500,000 grant to deploy wastewater surveillance products for global health security.

Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, announced today that it has received a $500,000 grant award from the Gates Foundation. This funding will support the deployment of Ceres’ wastewater biosecurity products to global health testing sites across Africa and India.

Global biosecurity has become a top priority, and wastewater surveillance for pathogens in low- and middle-income countries (LMICs) is crucial for pandemic preparedness and prevention. There is a significant need for standardized, low-cost, and easy-to-use wastewater sample processing methods across diverse geographic locations.

This funding will focus on establishing a sustainable supply chain for wastewater testing tools, ensuring that LMICs can continue to monitor priority pathogens beyond the life of the grant. By lowering barriers to adoption, Ceres aims to strengthen national disease surveillance systems and accelerate progress towards global health security.

“Global biosecurity has become a top priority, and wastewater surveillance is one of the most effective ways to monitor pathogens of concern at the population level,” said Ross Dunlap, CEO of Ceres Nanosciences. “By deploying our sample processing products to sites across Africa and India, we can help public agencies act faster, respond to outbreaks earlier, and build resilient surveillance systems that protect millions of lives. We are grateful to the Gates Foundation for supporting this critical need.”

 

Read more here.

Recent News

10/17/2025

BRAINBox Solutions Announces Publication in JAMA Network OPEN of Major Analysis of Initial HeadSmart II Trial Concussion Patients

BRAINBox Solutions today announced the publication in JAMA Network OPEN of a major analysis of the first 1,000 patients with suspected concussion (mild traumatic brain injury or mTBI) in its pivotal, HeadSMART II study of its initial test, BRAINBox TBI, for concussion diagnosis and prognosis. The analysis, the largest of its kind, identified patient characteristics

10/16/2025

Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food and Drug Administration (FDA) Commissioner’s National Priority Voucher (CNPV) Pilot Program. This designation recognizes Phlow’s leadership in advancing domestic manufacturing of essential and life-changing medicines

10/16/2025

Civica To Launch Long-Acting Insulin Glargine in the US in January 2026

Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price in the current long-acting insulin market. Civica insulin glargine will be available in the United States beginning January 1, 2026. In California, the product will carry the “CalRx” brand. “Civica will provide insulin